Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:5/21/2013)... Daulton, CEO of Mammotome, a division of Devicor Medical Products, ... Cincinnati chapter of the Association for Corporate ... executive who is also a breast cancer survivor, led the ... of 2010. Daulton will be presented with the award at ... on May 22. The ACG Deal Maker Awards ...
(Date:5/21/2013)... , May 21, 2013 /PRNewswire-iReach/ -- The 2013 ... NJ has attracted the greatest number of "Emerging" ... President, Mark Alexay .  "No ... to attend this year.  The show,s still 4 months ... companies.  This is a big surprise and great ...
(Date:5/21/2013)... CLARA, Calif. , May 21, 2013 ... game-changing embedded-ultrasound platform, today announced the introduction ... that allows complete network-based communications with all ... its latest embedded-ultrasound technology, including this new ... Sao Paulo, Brazil from ...
Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2
... Arbor Pharmaceuticals announced today that it has filed ... Food and Drug Administration (FDA).  The recently filed product ... which provides seven years of market exclusivity. In addition, ... this product primarily due to the safety advantages it ...
... MADISON, Wis., Dec. 1, 2011 Novelos Therapeutics, Inc. ... treatment and diagnosis of cancer, today announced the pricing of ... unit for gross proceeds of $5,904,000.  Each unit consists of ... one share of common stock.  The warrants will have an ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2Novelos Therapeutics Prices $5.9 Million Public Offering 2
(Date:5/21/2013)... Calabash, NC (PRWEB) May 21, 2013 ... Lodges is synonymous with comprehensive travel guides. Brunswick Plantation ... play golf packages that include access to 27 holes ... available golf courses in North Carolina, knowing the ... Resorts and Lodges takes away the overwhelming task of ...
(Date:5/21/2013)... (PRWEB) May 22, 2013 About one ... the Fertility Clinics industry one of the ... assists patients who are unable to conceive naturally through ... popular of which is in-vitro fertilisation (IVF) cycles. Over ... cycles in Australia has increased by 4.4% per annum ...
(Date:5/21/2013)... Steven Reinberg HealthDay Reporter , , TUESDAY, May ... a major cause of sleep apnea in children, and ... learning for these kids, it did help them with ... finds. Sleep apnea is a condition that causes ... a greater improvement in sleep with the surgery, and ...
(Date:5/21/2013)... University of Iowa,s vice president for research and ... exascale computing, the next generation of supercomputers designed ... to the human mind. , Daniel Reed will ... of the House Subcommittee on Energy, titled, "America,s ... begins at 10 a.m. in Room 2318 of ...
(Date:5/21/2013)... Norton HealthDay Reporter , , TUESDAY, May 21 ... two genes may be at increased risk of suffering ... The researchers hope they can use the findings ... pregnant women who are vulnerable to postpartum depression, which ... study, reported in the May 21 issue of the ...
Breaking Medicine News(10 mins):Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Iowa VP for Research addresses next-generation supercomputers at congressional hearing 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 3
... FUND RESEARCH TO CURE CANCER IN ... DOGS - RESEARCH ALSO BENEFITING HUMANS, DENVER, Jan. 18 ... dogs and or very special humans in your life.,Morris Animal Foundation ... contributing $50 or more to the MAF canine,cancer cure research effort. ...
... LifeSync Corporation is,pleased to announce the appointment of ... McLane comes to LifeSync Corporation after,seven years at ... she,most recently held the position of Executive Director ... McLane spent over 13,years at C.R. Bard in ...
... by Christian Rocker and Top ,Clean, Comedian Round Out the All-Star ... ... 18 Our Savior Lutheran Church,announced today an all-star line-up for its ... Sure to satisfy all in,attendance, LoveFest offers its most diverse casting to ...
... dual implantation of radioactive seeds and chemotherapy wafers ... led by specialists at the Neuroscience Institute at ... , The study, published in the February issue ... treated with simultaneous implantation of radioactive seeds and ...
... are aimed at getting action from Cardinal George and Public Official ... ... 17 Three years ago, health care activist,Joe Novak -- during a ... end the abuses of not-for-profit health,care systems, especially those that are Catholic., ...
... Medical,Center has held extensive settlement discussions with the Public ... their apparent negotiating,tactic we remain optimistic that these discussions ... The filing of a lawsuit was unnecessary given the ... not receive any document outlining,Mr. Olvera,s specific claims until ...
Cached Medicine News:Health News:Unique Gift for Valentine's Day: Canine Cancer Campaign Customized Dog Tag - for Your Dog or as a Beautiful Piece of Jewelry for a Special Human 2Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:LoveFest 6 Taps Hollywood Actress to Headline Annual Abstinence Conference 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:Hollywood Presbyterian Medical Center Responds to ACLU Lawsuit 2
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Medicine Products: